The Heart Drug That Wants to Beat BMS and Cytokinetics at Their Own Game
Edgewise Therapeutics just dropped Phase 2 data for a heart drug that works differently from anything on the market. Wall Street responded by selling the stock 10%, and some analysts think that's a mistake.
Imagine you're in a boxing ring. Your two opponents have been trading punches for months, building muscle, signing endorsement deals. And you walk in with a completely different fighting style.
That's basically what Edgewise Therapeutics just did in the hypertrophic cardiomyopathy (HCM) market. The Boulder-based biotech dropped Phase 2 data for its heart drug EDG-7500, and the results were strong enough to set up a Phase 3 showdown with two heavyweights: Bristol Myers Squibb's Camzyos (mavacamten) and Cytokinetics' freshly launched Myqorzo (aficamten). Wall Street's reaction? A 10% stock drop. Because apparently, "really good" wasn't quite "mind-blowing."
Let's unpack what happened, why it matters, and whether Edgewise actually has a shot.
A Quick Primer on HCM (Without the Med School Jargon)
Hypertrophic cardiomyopathy is a condition where the heart muscle gets abnormally thick. Think of it like your heart is trying too hard: squeezing too forcefully, not relaxing properly, and sometimes blocking its own blood flow in the process. It affects roughly 1 in 500 people, and for decades, the treatment options were limited to beta-blockers, calcium-channel blockers, and, in severe cases, open-heart surgery.
Then came cardiac myosin inhibitors (CMIs), a new class of drugs that calm the heart's overenthusiastic squeeze. BMS's Camzyos arrived first in 2022. Cytokinetics' Myqorzo got FDA approval in December 2025. Together, they've turned HCM into a multi-billion-dollar market, with analysts projecting the global space could hit $2.3 billion or more by 2030.
But both drugs share a common problem. They work by directly shutting down myosin motors (the molecular engines that make your heart contract). That's effective, sure. But it's a bit like fixing a car that accelerates too fast by cutting power to the engine. You slow it down, but you also risk stalling it entirely. Both drugs require careful dose titration and regular heart imaging to make sure they don't suppress the heart's pumping function too much.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
EDG-7500 doesn't directly inhibit the myosin motor. Instead, it targets other proteins in the heart's contractile machinery (called the sarcomere) to change the timing of how the heart contracts and relaxes. Picture a drummer in a band who's playing too fast and not pausing between beats. Camzyos and Myqorzo solve this by taking drumsticks away. EDG-7500 teaches the drummer better rhythm.
Specifically, EDG-7500 slows the speed of early contraction (when blood-flow obstruction starts) and speeds up relaxation during diastole (when the heart is supposed to be filling with blood). The company says this approach can reduce obstruction and improve symptoms without tanking the heart's overall pumping power.
That's the theory, anyway. The Phase 2 data suggest it might actually work.
The Numbers That Got Everyone Talking
The 12-week CIRRUS-HCM trial tested EDG-7500 in two groups: patients with obstructive HCM (where blood flow is physically blocked) and non-obstructive HCM (where the heart is stiff and symptomatic, but without a clear blockage).
In obstructive HCM, the results were genuinely impressive. About 90% of patients showed improvement in blood-flow obstruction. On the symptom side, patients reported a 24-point improvement on the Kansas City Cardiomyopathy Questionnaire (KCCQ), a standard quality-of-life score where a 5-point change is considered clinically meaningful. That's nearly five times the threshold.
NT-proBNP, a blood marker of heart failure stress, dropped dramatically: 74% of patients either normalized their levels or cut them in half. And 70% improved by at least one functional class on the NYHA scale (the standard grading system cardiologists use to rate heart failure severity).
Critically, no patient's heart pumping function (LVEF) dropped below 50%. That's the safety card Edgewise keeps playing, and it's a good one. The existing CMIs require echo-guided dose adjustments specifically to avoid that problem.
The Non-Obstructive Question Mark
Non-obstructive HCM is where things get more interesting, and more debatable. This is a patient population with very few options. BMS tried to crack it with mavacamten in the ODYSSEY-HCM trial. It failed. Aficamten's nHCM trial is still running.
EDG-7500's nHCM data showed a 65% mean reduction in NT-proBNP, with a stunning 88% of patients hitting normalization or a 50% drop. Diastolic relaxation improved by 37% (even better than the oHCM group). And 64% of patients gained at least one NYHA class.
But the KCCQ improvement in nHCM was 13 points. Still clinically meaningful by a wide margin. But not the 20-plus that some investors had been dreaming about. And in the world of biotech investing, "good but not great" can feel like a miss.
Why the Stock Dropped (and Why Some Analysts Think That's Wrong)
Edgewise shares fell roughly 10% after the data release on June 16, closing around $33.95 after opening near $35.21. The culprit? That nHCM KCCQ number.
RBC Capital analyst Leonid Timashev noted that the nHCM symptom improvement "likely underwhelmed some investor expectations," with the Street hoping for high teens or above 20 points. But he still called EDG-7500's efficacy "clearly competitive" and its safety record "unmatched in the space."
J.P. Morgan's Tessa Romero raised her price target to $53 and maintained an Overweight rating on Edgewise.
Truist, meanwhile, raised practical concerns: Phase 3 enrollment timelines, the possibility that regulators might want a head-to-head trial against approved drugs, and the long wait before pivotal data arrives. Those are real overhangs for a stock that needs patience.
The consensus among most covering analysts? Strong Buy ratings with significant upside to current price targets. The bull case: differentiated safety, competitive efficacy, and a shot at both oHCM and nHCM in a market where penetration is still low.
The Competitive Landscape Is Getting Crowded
Camzyos is the 800-pound gorilla. It's been on the market since 2022, with its most recent quarterly revenue reaching $353 million in Q4 2025, and has deep prescriber familiarity. BMS isn't going anywhere.
Myqorzo is the hungry newcomer. Approved just six months ago, Cytokinetics is in early commercial ramp-up. The company estimates that Camzyos has only reached 15-20% of eligible patients, meaning there's enormous room for the overall myosin-inhibitor category to grow rather than just cannibalize. Cytokinetics has officially targeted more than 50% new-to-brand prescription share by the end of 2026.
And now Edgewise wants a seat at the table. But it's years behind: Phase 3 doesn't even start until Q4 2026, with pivotal data presumably arriving in 2028 or 2029 at the earliest.
So what's the pitch to doctors who already have two options?
The Case for (and Against) EDG-7500
The bull case boils down to three words: safety, simplicity, scope.
On safety, EDG-7500 hasn't pushed any patient's LVEF below 50%. No atrial fibrillation events were reported in earlier trial parts. For a chronic disease where patients take medication for life, that matters enormously.
On simplicity, the mechanism's self-limiting nature could theoretically support fixed-dose regimens without the frequent echocardiograms that Camzyos and Myqorzo require. That's a massive practical advantage for both patients and healthcare systems.
On scope, EDG-7500 is being developed for both obstructive and non-obstructive HCM from the start. If the nHCM data hold up in Phase 3, Edgewise would have a meaningful edge in a population where mavacamten already failed and aficamten's results are unknown.
The bear case is timing and uncertainty. Phase 3 hasn't started. The nHCM symptom data, while positive, aren't a slam dunk. By the time EDG-7500 could reach the market (optimistically 2030), Camzyos and Myqorzo will be deeply entrenched with years of real-world data. And regulators might demand a head-to-head trial, which would add years and risk.
There's also the open question of what exactly EDG-7500 binds to. The company describes its mechanism through sarcomere protein-protein interactions but hasn't publicly disclosed the specific molecular target. That's unusual for a drug heading into late-stage trials, and it makes independent scientific validation harder.
What Happens Next
Edgewise plans to initiate Phase 3 in Q4 2026, pending regulatory discussions that will shape the trial's design, endpoints, and whether a comparator arm against existing CMIs is needed. The company will present full CIRRUS-HCM data at upcoming medical meetings, which should provide more granular detail on dose-response curves, subgroup analyses, and durability of effect.
The HCM market is entering its most competitive phase ever. Camzyos is scaling. Myqorzo is launching. And now EDG-7500 is knocking on the door with a genuinely different approach.
Whether "different" translates to "better" is a question that only Phase 3 can answer. But if you're a patient with HCM who's been told your options are limited, the fact that three companies are fighting over how best to treat your condition is, by itself, very good news.
Deals & M&A5 min read
Incyte Just Spent $1.25 Billion on a Disease Most People Haven't Heard Of
Incyte is paying $1.25 billion upfront (up to $2 billion total) for Vega Therapeutics and its Phase 3 von Willebrand disease drug. It's a massive bet on a bleeding disorder most people can't name, and Wall Street is cautiously on board.
